<DOC>
	<DOCNO>NCT02084953</DOCNO>
	<brief_summary>The purpose study determine whether BMS-791325 effect electrocardiogram ( ECG ) interval QT correct Fridericia 's method ( QTcF ) .</brief_summary>
	<brief_title>Study Determine Effect BMS-791325 ECG QTcF Interval Healthy Subjects</brief_title>
	<detailed_description>Primary Purpose : Other : This Phase 1 study clinical pharmacology thorough QT study .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Healthy men woman , age 18 49 yr old BMI 18 32 Women must pregnant breastfeed Any significant acute chronic medical illness A personal history clinically relevant cardiac disease , symptomatic asymptomatic arrhythmia , presyncope syncopal episode , additional risk factor torsades de pointes ( eg , heart failure ) History hypokalemia , personal history family history prolong QT interval , family history sudden cardiac death young age History biliary disorder , include Gilbert 's disease DubinJohnson disease Inability swallow multiple tablet consecutively Any follow 12lead electrocardiogram ( ECG ) prior study drug administration : PR ≥ 210 msec , QRS ≥ 120 msec , QT ≥ 500 msec , QTcF ≥ 450 msec , Heart Rate ( HR ) &lt; 45 bpm Second third degree heart block prior study drug Positive urine screen drug abuse Positive blood screen hepatitis C antibody , hepatitis B surface antigen , Human Immunodeficiency Virus ( HIV ) 1 , 2 antibody Any follow lab result outside range specify prior dosing : Alanine aminotransferase ( ALT ) &gt; upper limit normal ( ULN ) , Aspartate aminotransferase ( AST ) &gt; ULN , Total bilirubin &gt; ULN , Direct bilirubin &gt; ULN , Creatinine &gt; ULN , Serum potassium &lt; low limit normal ( LLN ) , Serum magnesium &lt; LLN History allergy Moxifloxacin , BMS791325 , nonstructural protein 5B ( NS5B ) nonnucleoside inhibitor related compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>